RESEARCH ARTICLE

Supporting surveillance capacity for antimicrobial resistance: Laboratory capacity strengthening for drug resistant infections in low and middle income countries [version 1; peer review: 2 approved, 1 approved with reservations]

Anna C. Seale 1,2, Coll Hutchison 1, Silke Fernandes 1, Nicole Stoesser 3, Helen Kelly 1, Brett Lowe 3,4, Paul Turner 3,5, Kara Hanson 1, Clare I.R. Chandler 1, Catherine Goodman 1, Richard A. Stabler 1, J. Anthony G. Scott 1,3,4

1London School of Hygiene & Tropical Medicine, London, WC1E 7HT, UK
2College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia
3Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7BN, UK
4KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
5Cambodia Oxford Medical Research Unit, Siem Reap, Cambodia

Abstract

Development of antimicrobial resistance (AMR) threatens our ability to treat common and life threatening infections. Identifying the emergence of AMR requires strengthening of surveillance for AMR, particularly in low and middle-income countries (LMICs) where the burden of infection is highest and health systems are least able to respond. This work aimed, through a combination of desk-based investigation, discussion with colleagues worldwide, and visits to three contrasting countries (Ethiopia, Malawi and Vietnam), to map and compare existing models and surveillance systems for AMR, to examine what worked and what did not work.

Current capacity for AMR surveillance varies in LMICs, but systems in development are focussed on laboratory surveillance. This approach limits understanding of AMR and the extent to which laboratory results can inform local, national and international public health policy. An integrated model, combining clinical, laboratory and demographic surveillance in sentinel sites is more informative and costs for clinical and demographic surveillance are proportionally much lower.

The speed and extent to which AMR surveillance can be strengthened depends on the functioning of the health system, and the resources available. Where there is existing laboratory capacity, it may be possible to develop 5-20 sentinel sites with a long term view of establishing comprehensive surveillance; but where health systems are weaker and laboratory infrastructure less developed, available expertise and resources may limit this to 1-2 sentinel sites. Prioritising core functions, such as automated blood cultures, reduces investment at each site. Expertise to support AMR surveillance in LMICs may come from a variety of

Reviewer Status

Invited Reviewers

<table>
<thead>
<tr>
<th>Invited Reviewers</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elizeus Rutebemberwa</td>
<td>report</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Makerere University College of Health Sciences, Kampala, Uganda</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lisa M. Bebell</td>
<td>report</td>
<td>report</td>
<td>report</td>
</tr>
<tr>
<td>Massachusetts General Hospital, Boston, USA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laura Shallcross</td>
<td>report</td>
<td>report</td>
<td>report</td>
</tr>
<tr>
<td>University College London, London, UK</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Any reports and responses or comments on the article can be found at the end of the article.
international, or national, institutions. It is important that these organisations collaborate to support the health systems on which AMR surveillance is built, as well as improving technical capacity specifically relating to AMR surveillance. Strong collaborations, and leadership, drive successful AMR surveillance systems across countries and contexts.

**Keywords**
antimicrobial, antibiotic resistance, drug, infection, surveillance

**Corresponding author:** Anna C. Seale (anna.seale@lshtm.ac.uk)

**Author roles:**
- **Seale AC:** Conceptualization, Funding Acquisition, Investigation, Methodology, Supervision, Writing – Original Draft Preparation;
- **Hutchison C:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing;
- **Fernandes S:** Conceptualization, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing;
- **Stoesser N:** Conceptualization, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing;
- **Kelly H:** Conceptualization, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing;
- **Lowe B:** Conceptualization, Writing – Review & Editing;
- **Turner P:** Conceptualization, Writing – Review & Editing;
- **Hanson K:** Conceptualization, Writing – Review & Editing;
- **Stabler RA:** Conceptualization, Writing – Review & Editing;
- **Chandler CIR:** Conceptualization, Writing – Review & Editing;
- **Goodman C:** Conceptualization, Writing – Review & Editing;
- **Scott JAG:** Conceptualization, Funding Acquisition, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**Grant information:** This is an independent study commissioned by the Wellcome Trust (202959) and funded by Department of Health, UK. Anthony Scott and Anna Seale are funded by The Wellcome Trust (098532, 205184, respectively). Nicole Stoesser is funded through a University of Oxford/Public Health England Clinical Lectureship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Copyright:** © 2017 Seale AC et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Seale AC, Hutchison C, Fernandes S et al. Supporting surveillance capacity for antimicrobial resistance: Laboratory capacity strengthening for drug resistant infections in low and middle income countries [version 1; peer review: 2 approved, 1 approved with reservations] Wellcome Open Research 2017, 2:91 https://doi.org/10.12688/wellcomeopenres.12523.1

**First published:** 26 Sep 2017, 2:91 https://doi.org/10.12688/wellcomeopenres.12523.1
Introduction
Since the introduction of antibiotics into medicine in the 1940s, they have provided dependable treatment for many infectious diseases. The emergence of antimicrobial resistance (AMR) and related drug resistant infections (DRIs) challenges this. One of the early priorities identified to tackle the emergence of AMR and DRIs is to strengthen surveillance of AMR in low and middle income countries (LMICs).

Despite LMICs having the highest incidence of infection (and associated mortality and morbidity) there are significant gaps in our understanding of the aetiology and incidence of infectious diseases in these contexts. This constrains national governments and international organisations in their efforts to detect evolving trends and emerging threats.

Data on the true prevalence of AMR in LMICs are limited. In 2014, the World Health Organization (WHO) summarized the most recent information on AMR surveillance for a selected set of nine bacteria–antibacterial drug combinations of public health importance from 129 Member States. Among WHO regions, the greatest volume of country-level data were obtained from the European Region and the Region of the Americas, where longstanding regional surveillance and collaboration exist. In contrast, data from LMIC were underrepresented, and in some countries, lacking. However, there is no evidence to suggest that the burden of AMR for common pathogens in LMICs is not increasing in line with the rest of the world, and can be the place of emergence. Understanding current capacity for AMR surveillance in LMICs is important, as well as considering how to develop capacity in different settings and contexts, and their requisite costs.

Modelled estimates put the number of AMR attributable deaths per year in Europe at 25,000 with €1.5 billion in associated health care costs and productivity losses; in the United States there are 23,000 deaths per year attributable to AMR at a direct cost of US$20 billion and an indirect cost of US$35 billion in productivity losses. There are no reliable estimates available on the economic losses due to AMR available from LMICs, but they are likely to be considerable. Despite the economic losses identified in high income countries, funding to tackle AMR has, until recently, been limited. This is in part because costs associated with establishing and running AMR surveillance were considered to be high. With a view to informing future capacity building for AMR surveillance in LMIC settings, this work aimed to characterise the requirements for achieving capacity to detect the emergence of AMR at national levels. The specific objectives were:

i) To map and compare existing models for laboratory system strengthening (for AMR surveillance), including the identification of specific contexts and geographical settings where certain models have been more or less successful, analysis of challenges and barriers in different geographical and sociodemographic contexts, consideration of costs and sustainability and assessment of governance issues, including the ability to share data.

ii) To map and compare existing AMR surveillance systems in at least three countries, identifying different approaches for monitoring emergence and spread of resistance in different countries or regional settings, including the range of baseline data gathered, the best models and mechanisms for surveillance, capacity strengthening and training in the different country or regional settings.

A fully formatted report is included as Supplementary File 1.

Methods
A team with expertise in health systems, health economics, anthropology, microbiology, laboratory capacity, surveillance, and epidemiology was brought together. This group discussed and developed an initial outline of a conceptual model for AMR surveillance on which to frame the desk based analysis, case studies and costing of AMR (Figure 1).

Desk based analysis and conceptual model
A desk-based analysis of capacity for AMR surveillance in Sub-Saharan Africa and South-east Asia was done, first by reviewing the WHO’s AMR report and then looking at those countries that had been able to contribute data, and identifying which components of the conceptual model they had put in place (or other) to do this. The challenges faced in these systems were also considered. Where there were few or no data in WHO sub-regions, examples of other surveillance systems that had been established, outside of the context of AMR surveillance were reviewed.

Case studies
Site visits were made to Malawi, Ethiopia and Vietnam, and capacity in these countries reviewed according to the components included in the conceptual model and the functions that would be needed to improve/develop AMR surveillance, as well as the strengths of the systems and models in place. This work involved extensive review of relevant guidelines and health system and policy literature, as well as discussions with in-country personnel, including laboratory staff, policy-makers, clinicians, microbiologists, veterinarians and epidemiologists.

Analytic framework
We identified the functions, sub-functions and activities needed for AMR surveillance at a national and site level, and defined four levels of AMR surveillance capacity involving increasing complexity. Capacity at Level 1 represents the most limited system, with incomplete clinical data, minimal clinical investigation and no laboratory testing. At level 2 there is some laboratory testing but no standardization of processes in place. Level 3 represents a core surveillance system with standardized processes, focusing on invasive disease in children under five years and the identification and antimicrobial susceptibility testing of WHO priority pathogens (Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, Streptococcus pneumoniae, Acinetobacter baumannii, Salmonella spp., Shigella spp., Neisseria gonor rhoeae). Level 4 represents extended AMR surveillance capacity, with capacity to include AMR surveillance from all patients and
all sample types. The four functions at the sentinel site level were 1) clinical admission assessment & investigation; 2) isolate identification and susceptibility testing; 3) isolate storage (local) & referral to reference laboratory; and 4) data system and review. At the national level these functions were 1) leadership; 2) training; 3) quality assurance; and 4) national reference laboratory. Each function was further broken down into sub-functions; for example “clinical admission assessment & investigation” has four sub-functions, namely i) clinical admission assessment; ii) clinical data; iii) clinical investigation; and iv) training and quality assurance, all describing the different activities relevant for clinical surveillance. Components are detailed in Table 1 and Table 2.

Costing
In each sub-function, the interventions, activities and resources needed to move from one level to the next were defined. The costs of establishing and implementing (start-up costs), as well as running (recurrent costs) of the described activities were included and recorded following an ingredients approach, where unit costs and quantities were required to calculate total costs for each input. This allowed the cost estimates to be adapted more easily to different country settings, by applying local unit costs. The cost results were presented by year, ranging from year 1 to year 5.

Due to the different capacities and models used in the different sites that were visited, as well as logistical constraints, costs were assessed in a single highly functioning site in Kenya (KEMRI-Wellcome Trust Research Programme), where clinical, laboratory and demographic surveillance systems are integrated. We used site specific costs, for personnel, for subsequent specific country estimates. Data collection for the costing involved interviews with key personnel, review of key documents and observation of a functioning clinical, laboratory and demographic surveillance system. The approach to the costing was pragmatic, prioritising the most accurate recording of high cost items (with most influence on estimates of total cost). All information was collected and analysed in Excel 2016.

Results
Desk based analysis
Capacity for AMR surveillance varies between sub-Saharan Africa and South-east Asia, and within countries in these regions. In the WHO African region (AFRO), a recent review reported only 2 of the 47 AFRO member states (Ethiopia and South Africa) had national AMR plans in place\(^{10}\), and 7/47 members (Ethiopia, Ghana, Kenya, Lesotho, South Africa, Tanzania and Zimbabwe) had overarching national infection prevention and control (IPC)
<table>
<thead>
<tr>
<th>Level of surveillance sophistication increasing from left to right</th>
<th>Level 1: Limited</th>
<th>Level 2: Clinical history and examination, but no algorithms in use</th>
<th>Level 3: CORE</th>
<th>Level 4: EXTENDED</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aim of AMR surveillance</td>
<td>Surveillance data drive local policy</td>
<td>Surveillance data drive national policy and international policy</td>
<td>Surveillance data drive national policy and international policy</td>
<td>Surveillance data drive national policy and international policy</td>
</tr>
<tr>
<td>Clinical admission assessment and investigation</td>
<td>Clinical history and examination, but no algorithms in use</td>
<td>Paper-based documentation of clinical history and examination</td>
<td>Systematic clinical history and examination according to clinical algorithms in core patient group (&lt;5 years)</td>
<td>Samples transported according to local standard operating procedures</td>
</tr>
<tr>
<td>Clinical data</td>
<td>Clinical investigations ad-hoc</td>
<td>Clinical investigation based on clinical findings but not standardized</td>
<td>Routine training to surveillance SOPs</td>
<td>Local lab data system linked to clinical data on site</td>
</tr>
<tr>
<td>Training and quality assurance</td>
<td>Not done</td>
<td>No registration system</td>
<td>Routine training to surveillance SOPs</td>
<td>Local lab data system with manual linkage to lab isolates</td>
</tr>
<tr>
<td>Isolate identification and susceptibility testing</td>
<td>Sample not transported routinely</td>
<td>Paper-based registration (logbook)</td>
<td>Sample registration system</td>
<td>Automated blood culture with processing the WHO 9 priority pathogens according to SOPs</td>
</tr>
<tr>
<td>Sample transport from clinical to laboratory</td>
<td>No blood cultures</td>
<td>No blood cultures</td>
<td>No blood cultures</td>
<td>No blood cultures</td>
</tr>
<tr>
<td>Culture</td>
<td>No culture</td>
<td>No culture</td>
<td>No culture</td>
<td>No culture</td>
</tr>
<tr>
<td>Susceptibility testing</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sub-functions</th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
<th>Level 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Functions</td>
<td>Surveillance data drive local policy</td>
<td>Surveillance data drive national policy</td>
<td>Surveillance data drive national policy and international policy</td>
<td>Surveillance data drive national policy and international policy</td>
</tr>
<tr>
<td>Clinical admission assessment and investigation</td>
<td>Clinical history and examination, but no algorithms in use</td>
<td>Paper-based documentation of clinical history and examination</td>
<td>Systematic clinical history and examination according to clinical algorithms in core patient group (&lt;5 years)</td>
<td>Samples transported according to local standard operating procedures</td>
</tr>
<tr>
<td>Clinical data</td>
<td>Clinical investigations ad-hoc</td>
<td>Clinical investigation based on clinical findings but not standardized</td>
<td>Routine training to surveillance SOPs</td>
<td>Local lab data system linked to clinical data on site</td>
</tr>
<tr>
<td>Training and quality assurance</td>
<td>Not done</td>
<td>No registration system</td>
<td>Routine training to surveillance SOPs</td>
<td>Local lab data system with manual linkage to lab isolates</td>
</tr>
<tr>
<td>Isolate identification and susceptibility testing</td>
<td>Sample not transported routinely</td>
<td>Paper-based registration (logbook)</td>
<td>Sample registration system</td>
<td>Automated blood culture with processing the WHO 9 priority pathogens according to SOPs</td>
</tr>
<tr>
<td>Sample transport from clinical to laboratory</td>
<td>No blood cultures</td>
<td>No blood cultures</td>
<td>No blood cultures</td>
<td>No blood cultures</td>
</tr>
<tr>
<td>Culture</td>
<td>No culture</td>
<td>No culture</td>
<td>No culture</td>
<td>No culture</td>
</tr>
<tr>
<td>Susceptibility testing</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Isolate storage (local) and referral to reference lab</td>
<td>Storage of isolates</td>
<td>Transport to reference lab</td>
<td>Training and quality assurance</td>
<td>Data system and review</td>
</tr>
<tr>
<td>-----------------------------------------------------</td>
<td>--------------------</td>
<td>---------------------------</td>
<td>-----------------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>Level 1</td>
<td>No biorepository, or no documentation of stored samples.</td>
<td>Isolates are not transferred to reference lab</td>
<td>Not done</td>
<td>None</td>
</tr>
<tr>
<td>Level 2</td>
<td>Biorepository of isolates, paper-based database with storage of at least a subset of resistant isolates defined by local policy (-20 or -80C)</td>
<td>Isolates are transferred to ref lab on an ad-hoc basis</td>
<td>Ad hoc</td>
<td>Not done</td>
</tr>
<tr>
<td>Level 3 - CORE</td>
<td>Biorepository of isolates, with paper or electronic database with storage of all resistant isolates (-20 or -80C) defined by national policy</td>
<td>Isolates are transferred to ref lab at least annually but not according to defined SOPs</td>
<td>Routine training for isolate storage and transport SOPs</td>
<td>Local lab data system with manual linkage to clinical data on site; system not linked to national network; paper based or electronic biorepository database that is not linked</td>
</tr>
<tr>
<td>Level 4 - EXTENDED</td>
<td>Biorepository of isolates, with electronic database of all stored resistant isolates defined by national and/or international policy, maintained at -80C.</td>
<td>Isolates are transferred to ref lab at least annually according to international standards for biosafety</td>
<td>Routine training for isolate storage and transport SOPs; Quality assurance of lab biorepository with external assessment</td>
<td>Local lab data system electronically linked to clinical data and automatically linked to national network</td>
</tr>
<tr>
<td>Level of surveillance sophistication</td>
<td>Level 1 - Limited</td>
<td>Level 2 - CORE</td>
<td>Level 3 - CORE</td>
<td>Level 4 - EXTENDED</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>-------------------</td>
<td>----------------</td>
<td>----------------</td>
<td>--------------------</td>
</tr>
<tr>
<td><strong>Aim of AMR surveillance</strong></td>
<td>Limited</td>
<td>Surveillance data drive national policy and international policy</td>
<td>Surveillance data drive national policy and international policy</td>
<td>Surveillance data drive national policy and international policy</td>
</tr>
<tr>
<td><strong>Leadership</strong></td>
<td>None - no national coordinating body</td>
<td>National coordinating body but limited national data</td>
<td>National coordinating body but limited national data</td>
<td>National coordinating body but limited national data</td>
</tr>
<tr>
<td><strong>Data analysis</strong></td>
<td>None - no national coordinating body</td>
<td>National coordinating body but limited national data</td>
<td>National coordinating body but limited national data</td>
<td>National coordinating body but limited national data</td>
</tr>
<tr>
<td><strong>Assessment of evidence</strong></td>
<td>None - no national coordinating body</td>
<td>National coordinating body but limited national data</td>
<td>National coordinating body but limited national data</td>
<td>National coordinating body but limited national data</td>
</tr>
<tr>
<td><strong>Intervention</strong></td>
<td>None - no national coordinating body</td>
<td>National coordinating body but limited national data</td>
<td>National coordinating body but limited national data</td>
<td>National coordinating body but limited national data</td>
</tr>
<tr>
<td><strong>Laboratory</strong></td>
<td>None - no national coordinating body</td>
<td>National coordinating body but limited national data</td>
<td>National coordinating body but limited national data</td>
<td>National coordinating body but limited national data</td>
</tr>
<tr>
<td><strong>Clinical</strong></td>
<td>None - no national coordinating body</td>
<td>National coordinating body but limited national data</td>
<td>National coordinating body but limited national data</td>
<td>National coordinating body but limited national data</td>
</tr>
<tr>
<td><strong>Data</strong></td>
<td>None - no national coordinating body</td>
<td>National coordinating body but limited national data</td>
<td>National coordinating body but limited national data</td>
<td>National coordinating body but limited national data</td>
</tr>
<tr>
<td><strong>Quality Assurance</strong></td>
<td>None - no national coordinating body</td>
<td>National coordinating body but limited national data</td>
<td>National coordinating body but limited national data</td>
<td>National coordinating body but limited national data</td>
</tr>
<tr>
<td><strong>Storage of isolates</strong></td>
<td>None - no national coordinating body</td>
<td>National coordinating body but limited national data</td>
<td>National coordinating body but limited national data</td>
<td>National coordinating body but limited national data</td>
</tr>
<tr>
<td><strong>Transport to reference lab</strong></td>
<td>None - no national coordinating body</td>
<td>National coordinating body but limited national data</td>
<td>National coordinating body but limited national data</td>
<td>National coordinating body but limited national data</td>
</tr>
<tr>
<td><strong>Site lab</strong></td>
<td>None - no national coordinating body</td>
<td>National coordinating body but limited national data</td>
<td>National coordinating body but limited national data</td>
<td>National coordinating body but limited national data</td>
</tr>
<tr>
<td><strong>Reference lab</strong></td>
<td>None - no national coordinating body</td>
<td>National coordinating body but limited national data</td>
<td>National coordinating body but limited national data</td>
<td>National coordinating body but limited national data</td>
</tr>
</tbody>
</table>

**Training**
- Clinical: Training programmes train the "trainers" in core surveillance procedures.
- Laboratory: Training programmes train the "trainers" in core lab surveillance procedures.
- Data: Training programmes train the "trainers" in core data surveillance procedures.

**Clinical Surveillance**
- Site lab: Annual audit of clinical surveillance at sites.
- Reference lab: Annual audit of clinical surveillance at sites.
- Clinical: National training module for core clinical surveillance procedures.
- Laboratory: National reference laboratory, does QA with repeat testing of a subset of isolates.
- Data: National laboratory, QA with repeat testing of a subset of isolates, can do molecular testing (e.g. PCR) and/or local or international collaboration in place for next generation sequencing of isolates.

**Laboratory**
- Site lab: QA assessment of laboratory site.
- Reference lab: QA assessment of laboratory site.

**Data**
- Site lab: Support for automated sharing of data from sites for national aggregation.
- Reference lab: Support for automated sharing of data from sites for national aggregation.

**Quality Assurance**
- Site lab: Quarterly audit of clinical data submitted through automated systems and comparison with other sites.
- Reference lab: Quarterly audit of clinical data submitted through automated systems and comparison with other sites.

**Storage of isolates**
- Site lab: Support for automated sharing of data from sites for national aggregation.
- Reference lab: Support for automated sharing of data from sites for national aggregation.

**Transport to reference lab**
- Site lab: Support for automated sharing of data from sites for national aggregation.
- Reference lab: Support for automated sharing of data from sites for national aggregation.

**Isolates**
- Site lab: Isolates are not transferred to reference lab.
- Reference lab: Isolates are transferred to ref lab at least annually according to international standards.

**Isolates**
- Site lab: Isolates are not transferred to reference lab.
- Reference lab: Isolates are transferred to ref lab at least annually according to international standards.

**Isolates**
- Site lab: Isolates are not transferred to reference lab.
- Reference lab: Isolates are transferred to ref lab at least annually according to international standards.
policies\textsuperscript{11}. Establishment of AMR surveillance is limited, but capacity is being developed, for example in 24 hospital laboratories in Ghana\textsuperscript{12}. In contrast, South-East Asian countries have, are developing, or are initiating AMR surveillance systems, for example, Thailand, Vietnam, and Cambodia\textsuperscript{13}, respectively. This is in part supported by the more advanced development of networks and collaborations for AMR surveillance. Networks and examples of AMR surveillance and stewardship programmes are described in detail in Supplementary File 1, as well as surveillance of other infectious diseases. AMR surveillance strategies could also learn from and benefit from recent laboratory strengthening efforts as an important element of the work against the Ebola epidemic in West Africa since 2014 (Supplementary File 1: Box 3) and for specific diseases, for example rotavirus (Supplementary File 1: Box 4)\textsuperscript{14}.

Emerging themes in strengthening laboratory capacity for AMR surveillance included:

1. Leadership
Leadership, and the national policy addressing AMR, as well as international collaboration, are necessary to strengthen AMR surveillance in LMIC countries, to ensure an enabling policy environment. However expertise in microbiology is limited in these settings, and, whilst in the longer term this capacity is important to develop, in the interim leaders may need to be drawn from clinical infectious diseases and public health. Leaders are important for advocacy/championing, and for local credibility of the surveillance effort, as well as providing the focal point for activities.

2. Training
Where health systems are weak and still developing, there is a need to develop human resources across cadres of staff: clinical, laboratory and data management. Well-trained staff are likely to move elsewhere for better salaries; it is important that there is sufficient budget to ensure staff can be recruited and retained.

3. Laboratory quality assurance
In terms of strengthening laboratory capacity, it is clear that inadequate laboratory infrastructure limits the quality and the ability to reliably detect pathogens and conduct antimicrobial susceptibility testing.

There are different options for models of AMR surveillance (outlined in Supplementary File 1 and summarised in Supplementary File 1: Table 1). Overall, a model with active, continuous, comprehensive integrated population and laboratory disease surveillance would provide the most robust, comprehensive data. However, within the constraints of resources, an appropriately designed sentinel site system would also be appropriate. Whilst it would be feasible to assess AMR outside of a health care context, for example through cross-sectional studies of population colonisation (as part of a population based survey), these would not include surveillance of the most serious drug resistant infections, and fall outside the remit of public health surveillance as observational research studies requiring appropriate ethical approvals and individual informed consent.

Laboratory based surveillance identifies “a resistant organism”, but without clinical or population data cannot be fully interpreted and inform policy. To achieve the aim of AMR surveillance, and inform interventions, data are needed on:

- the proportion of the particular bacterial species identified (e.g. 	extit{Klebsiella pneumoniae}) that are resistant
- whether resistance is developing in a particular patient group (e.g. neonatal), or particular presentations (e.g. pneumonia)
- whether this is localised to a setting (e.g. ward, or geographic area)
- who seeks health care
- who lives in the population catchment area

Within the different models of surveillance, the functions are broadly consistent, and can be split into those provided at a national level and those provided at one or more sites, depending on capacity and the model in place, and including the themes identified above. At a national level, there is a need for leadership to support training, and quality across the system. A national AMR laboratory can support development of site laboratories and conduct more extensive testing (thus focussing resources, Supplementary File 1: Table 3, Figure 1). At a site level an integrated model includes development of laboratory capacity (isolate identification and susceptibility testing), clinical surveillance (systematic investigation of patients according to diagnosis), health care utilisation surveys (to assess representativeness of the health facility data) and census or enumeration data to determine the population catchment (Supplementary File 1: Table 1, Figure 1). These functions were used to cost AMR surveillance (Supplementary File 1: Tables 2 and 3) and consider how they were being achieved in the different models and contexts of the country case studies.

**Country case studies**

Full site reports are included in Supplementary File 1, the findings for each country are summarised here.

**Malawi.** Malawi faces substantial challenges due to extremely limited country resources, which reduces health system capacity. However, whilst it does not have the capacity for a comprehensive AMR surveillance system, it has been developing institutional infrastructure and policy for AMR surveillance. It also has considerable capacity through international collaboration and an academic centre of excellence (Malawi-Liverpool Wellcome Trust (MLW)) undertaking microbiological surveillance as part of a research programme. In order to take advantage of available research infrastructure i.e. sentinel surveillance capacity beyond Queen Elizabeth Central Hospital (QECH), the following should be considered for new surveillance sites in Malawi:

1. **Whether current capacity is representative of its area**

   The current AMR surveillance is conducted at the referral hospital (QECH), which limits the representativeness of the sampled patient population in relation to Blantyre district as a whole. It is therefore important to consider supporting
surveillance capacity development in other sites, using, if possible, the expertise available in country.

2. What the needs for investment/enhancement are in this setting
   Clinical surveillance and sampling is being strengthened with triage nurses to support systematic investigation in QECH. Microbiological surveillance is very strong, but electronic linking of clinical and microbiological databases is needed at this site and extension sites.

3. Whether the hospital is connected to national institutions, and regional networks
   There is growing collaboration between MLW, QECH and the Ministry of Health in Lilongwe, which would be needed to support extension of AMR surveillance sites.

Ethiopia. Ethiopia is developing a system for AMR surveillance that includes a national reference laboratory and sentinel regional laboratories across the country reporting data (continuous, passive surveillance). At present, whilst capacity is in development, there are some hospitals where the standard of clinical examination is adequate for surveillance, but there is limited microbiology laboratory capacity for processing specimens for culture, particularly blood cultures. Record keeping is not formalized or electronic, and there is potential for improved communication between the ward and the laboratory to link microbiology data to patients. In strengthening capacity for AMR surveillance, the following should be considered:

1. Determine whether the hospital(s) are epidemiologically representative
   It is important to include a range of health care settings for AMR surveillance; district hospitals, outside of the capital are more generalizable to the Ethiopian population as a whole than very urban settings.

2. Establish surveillance within the hospital
   Systems for development would be national guidelines supporting standardised clinical examination and systematic investigation. Laboratory capacity needs strengthening in terms of automated blood cultures to support AMR surveillance to a core level. Clinical and laboratory data should be linked, this could be through a double sided form with data collection for both.

3. Connect the site to a national and regional network
   The Ethiopian Public Health Institute is an arm of the Federal Ministry of Health and combines public health policy making with laboratory capacity in the same institution. Stronger regional links could support capacity development as well as continued partnership with international organizations.

Vietnam. Vietnam has established national infrastructure for AMR and has worked with regional networks and international collaborators to develop a surveillance system, including a national reference laboratory and twenty laboratories attached to district hospitals. The hospitals are public and broadly representative, there are functioning microbiology laboratories and the physical, legal and ethical capacity to link these records for anonymised aggregation at individual case level. In strengthening capacity for AMR surveillance, the following should be considered:

1. Consider the hospitals in the network
   The hospitals in the network are mid points in the hierarchical system in Vietnam and broadly representative. However, there would be considerable benefit from understanding health care utilisation patterns and population catchments to support laboratory data interpretation. In addition, given the ready accessibility and high volume use of antibiotics in Vietnam, surveillance may be needed at lower levels of health care.

2. Establish surveillance within hospital
   It is important that clinical examination and investigations are strengthened in the AMR surveillance system, to have the benefits of an integrated model, as well as the strengthening of laboratory microbiology services.

3. Build a network within country (and on to WHO)
   Many of this activities are in place in Vietnam, supported by strong national leadership and collaboration, and a hierarchical public health care system where national strategies can be implemented into care.

Costing
We developed a flexible model, based on an assumption that each country would have a number of sentinel sites with clinical and laboratory surveillance taking place in each site. We made an assumption that a country would aim for one surveillance facility per five million population, with a minimum of five surveillance facilities per country. However, cost results are presented for varying number of sites per country (2, 5 and 10), rather than for the target number of sites, with a focus on costing inputs required to achieve surveillance at level 3 (a core level) and level 4 (an extended level).

For a sentinel site (Table 1), each sub-function was broken down into all input activities and resources required to achieve the different levels of surveillance sophistication (core and extended) and summarized under “interventions” below each sub-function in clinical surveillance, laboratory surveillance, isolate storage and transport, data system and review (Supplementary File 1: Tables 4A–D). A number of inputs were costed independently of the sub-function framework, for example personnel costs required for laboratory surveillance or the cost of setting-up a laboratory including the cost of building and equipment. They are presented directly as inputs. The additional demographic component to surveillance was costed as an initial and final population enumeration round in year 1 and 5. Inputs of activities and resources required at the national surveillance level are shown in Table 2. The inputs (Supplementary File 1: Tables 4A–D and 5) were used to cost the surveillance components by determining quantities and unit costs at different levels of surveillance sophistication.

Costs depend on existing capacity, number of sentinel sites proposed for surveillance, and, across countries, variability in
costs of personnel. Illustrations are given for Kenya and Vietnam according to different numbers of sites (Supplementary File 1: Figures 7 and 8) across clinical, laboratory, national and demographic surveillance, as well as data system & review functions.

The largest contributor to the total cost of AMR surveillance is laboratory surveillance at the sentinel site (including isolate storage and transport to national reference laboratory), together with the national reference laboratory cost. These laboratory costs range, depending on number of sites and country, between 67% and 77% of the total cost at level 3 and between 78% and 85% at level 4. Within the laboratory cost the largest contributors to the total costs are the initial set up cost of the laboratory, and personnel. The increase in cost from core laboratory functions to extended laboratory functions is substantial (Supplementary File 1: Figures 6 and 7) and is driven by the increase in equipment and staff to support the increase in samples being processed (all sample types vs blood cultures), and isolates tested (all isolates vs WHO priority pathogens (excluding Neisseria gonorrhoeae, omitted as frequently tested for in outpatient settings with swabs)).

Within the overall envelope costed for AMR surveillance, the costs for clinical surveillance, data system and demographic surveillance are a much smaller proportion of total cost than laboratory surveillance. This is partly because for the clinical elements the costs of clinical staff providing care were not included, as in-post, except where additional clinical staff would be needed to undertake specific activities needed to support surveillance. In contrast, laboratory personnel costs were all included in the costing. However, this likely reflects the real-world situation, in terms of the need for recruitment of laboratory staff.

Conclusions

We aimed to map and compare existing models for laboratory system strengthening for AMR surveillance in LMICs. The work was based on desk review and three case studies on Ethiopia, Malawi and Vietnam, as well as costing based on a site visit at KEMRI Wellcome Trust Research Programme, Kilifi, Kenya. In the settings described in sub-Saharan Africa and South-east Asia, the AMR surveillance models are continuous, largely passive, laboratory based, using sentinel sites in country. An integrated model would be preferable for AMR surveillance so that data can be interpreted in a known clinical and demographic context, and case study countries were examined with this in mind.

It was apparent that the three countries visited were very different in terms of institutional architecture, health systems and AMR surveillance capacity, even on the short site visits undertaken for this work. For example, in Ethiopia there was early development of laboratory capacity in some broadly representative public hospitals, but no linked clinical data system, or population data; in Malawi there was very limited laboratory capacity in public hospitals, but a highly functioning research centre conducting surveillance in Blantyre, with high quality laboratory data, basic clinical data and a population denominator for urban and rural Blantyre; in Vietnam there was a broadly functioning laboratory capacity with a network of representative public hospitals across the country, supported by a consortium of international collaborators and with major investment but conducted at a level of the referral hierarchy (District hospitals), which is strongly susceptible to biases attributable to antibiotic access lower down in the referral hierarchy.

There were factors that were consistent in supporting and driving success in AMR capacity (Supplementary File 1: Figure 9). These include political commitment and collaboration amongst and between government and international stakeholders to utilise local and international expertise in supporting AMR surveillance development, as well as national policies on AMR surveillance developed within legal and ethical frameworks. Although an assessment of interventions in relation to AMR was beyond the scope of this work, political commitment and collaboration amongst stakeholders will also be crucial when considering and implementing these interventions (e.g. stewardship and antibiotic use), and initiating policy change.

It was clear that a functioning health system can support development of an integrated sentinel surveillance site system, progressing perhaps to comprehensive systems, more readily than a weaker health system. The integration of AMR surveillance into a health system requires an assessment of the form, state and functioning of a country’s health system. This is a central issue as the degree to which AMR surveillance will benefit national and local concerns (as opposed creating further burdens to staff) will largely be determined by the strength of its country’s health systems.

An important component, and common limitation of health systems in LMICs are the human resources to do work, across all cadres of staff, including clinical, laboratory, managerial, policy-making, data analysis, project management groups. Microbiological expertise is particularly limited. There were examples of support for human capacity development in the country case studies through Universities (national and international), research institutions (national and international) and interest in developing technical postgraduate programmes. However, where the health systems need strengthening there is insufficient training available in country to support the development of technical capacity to the level required. In these situations, AMR surveillance will be more likely to succeed if it is built up more slowly, using the expertise available from the most appropriate institutions. To ensure success at a “core level”, strengthening of surveillance may require a staged process with capacity built up over time. Here one site would be supported (which could be through a national reference laboratory, external partner, or research laboratory) to build capacity. An example of this would be utilising the expertise available in the Malawi Liverpool - Wellcome Trust Research Programme to support AMR surveillance in a district hospital. With development of capacity to a core level at a sentinel surveillance site, this site could subsequently serve as a training and support centre to develop capacity at another site, thus overcoming barriers to high quality surveillance when capacity is thinly spread across a weak health system. From this point, over time, a network of sites could be developed, as they are being developed in Vietnam, with the potential for sub-regional reference laboratories as the network expands.
Laboratory infrastructure with the capacity for standardised, quality diagnostics, are important. However, they have to be supported by appropriate logistical support (procurement, budget management), otherwise even the most highly equipped laboratories will not be able to function. With this in mind, securing a core set of standard activities, which can be maintained and result in useful, interpretable data is more important in the early stages of capacity development than the use of more advanced techniques. It also requires considerably less investment, and supporting five sentinel sites to a core level will likely produce more generalizable data than two sites, who have an extended capacity, for a similar investment.

Countries who have fragile and/or transitioning health systems are least able to respond to the present burden of infectious disease. Surveillance capacity depends on the existing health system and considerable investment is needed to develop laboratory infrastructure aligned to this. High level expertise in-country to provide advocacy, championing and trusted guidance to the Ministry of Health is important. Engagement with both the Ministry of Health and other national stakeholders is essential, combined with the expertise of in-country partners such as the public health organizations or academic institutions. Establishing whether these infections are treatable will inform treatment and facilitate a response; contributing to reducing the inequities in understanding disease burden worldwide.

Data availability
A full report on the data collected are included as Supplementary File 1. A costings tool in Excel 2016 can be made available through the corresponding author on request. This allows costs of AMR surveillance to be estimated based on the target number of sites in a country.

Author contributions
The team involved in this work included Anna C Seale (LSHTM), Coll Hutchison (LSHTM), Silke Fernandes (LSHTM), Helen Kelly (LSHTM), Nicole Stoeisser (University of Oxford), Paul Turner (University of Oxford), Kara Hanson (LSHTM), Clare Chandler (LSHTM), Catherine Goodman (LSHTM), Richard Stabler (LSHTM), Brett Lowe (University of Oxford) and J Anthony G Scott (LSHTM). The report was first drafted by Coll Hutchison, Silke Fernandes, Helen Kelly, Nicole Stoeisser and Anna Seale. The site visits were done by Anna Seale, Coll Hutchison, and Nicole Stoeisser and (for economics) Silke Fernandes. The costing analysis was done by Silke Fernandes.

Competing interests
No competing interests were disclosed.

Grant information
This is an independent study commissioned by the Wellcome Trust (202959) and funded by Department of Health, UK. Anthony Scott and Anna Seale are funded by The Wellcome Trust (098532, 205184, respectively). Nicole Stoesser is funded through a University of Oxford/Public Health England Clinical Lectureship.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements
In Ethiopia we would particularly like to thank the following institutions and personnel: Ethiopian Public Health Institute, Addis Ababa - Dr Adugna Woyessa, American Society for Microbiology, Laboratory Capacity Development Consultant - Dr Lourens Robberts; Centers for Communicable Disease Control, Ethiopia - Dr Yared Tedla, Laboratory Officer for the PEPFAR programme; Armauer Hansen Research Institute, Addis Ababa - Dr Abraham Aseffa, Scientific Director and Dr Taye Tolera Balcha (Director General); Haramaya University College of Health and Medical Sciences - Dr Yadeta Dessie, Dr Nega Assefa, Mr Melkamu Dedebo; Harar Regional Laboratory, Harar; Harar Hospital Laboratory, Haramaya University, Hiwot Fana Specialized Hospital, Harar. We would like to thank our collaborators in Malawi: particularly the Malawi-Liverpool-Wellcome Trust Research Unit at Queen’s Hospital, Blantyre including Prof Stephen Gordon, Dr Dean Everett, Brigitte Denis, Dr Rebecca Lester, Dr Jennifer Cornick, Dr Janilah Meghji, Dr Melita Gordon and Dr Nicholas Feasey. In Vietnam, we would like to thank the staff of the Oxford University Clinical Research Unit (OUCRU), including Guy Thwaites, Rogier Van Doorn, and Bui Huyen Trang, as well as Dr Nguyen Van Vinh Chau (Director, Hospital for Tropical Diseases) in Ho Chi Minh City, and Prof Nguyen Van Kinh, Prof Nguyen Vu Trung and Dr Le Thi Hoi from the National Hospital of Tropical Diseases; Prof Luong Ngoc Khue, Ngo Thi Bich Ha, Dr Nguyen Trong Khoa, Mr Cao Hung Thai from the Ministry of Health, Medical Services Administration (MSA). In Kenya, we would like to thank the KEMRI-Wellcome Trust Research Programme including Neema Mturi, Shebe Mohammed, Mary Muthomi, Brett Lowe, Salim Mwarumba, Oscar Kai, Moses Mosobo, Horace Gumba, Anthony Etyang, Eduard Sanders, Elinah Kaulu, Dorothy Tole, Lucian Mshote, Barnes Kitsao, Godfried Otieno. We would also like to thank others who gave their time and advice, including Prof Rob Heyderman, Dr Chris Parry, Fatima Serhan and Adam L. Cohen.

Supplementary material
Supplementary File 1: A fully formatted report with all Tables and Figures entitled “Supporting surveillance capacity for antimicrobial resistance: Laboratory Capacity Strengthening for Drug Resistant Infections in Low and Middle Income Countries”.

Click here to access the data.
References

Publication | Publisher Full Text | Free Full Text

Reference Source

PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text | Free Full Text

Reference Source

PubMed Abstract | Publisher Full Text | Free Full Text

Reference Source

Reference Source

Reference Source

Reference Source

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text
Laura Shallcross
Institute of Health Informatics, University College London, London, UK
Patrick Rockenschaub
Institute of Health Informatics, University College London, London, UK

Thank you for the invitation to review this article.
The authors provide a clear summary of why better surveillance systems are required to tackle AMR in LMICs and the barriers to achieving this goal in this context.

**General comments**

Although the authors mention the need for population surveillance and collection of clinical data, this article mainly focuses on the need to strengthen laboratory capacity at local, regional and national level. In my view this provides only part of the answer, as we also need to embed systems for monitoring antibiotic usage (prescribed and over the counter) and for measuring treatment outcomes. This is particularly relevant in settings where microbiology laboratories are poorly resourced. For example, a clinical assessment of whether the patient got better might in some cases be more informative than drug susceptibility testing.

The tables are a very useful tool to assess surveillance capacity. It would have been helpful to apply these criteria across each of the 3 countries presented to give a summary of the systems available in each setting.

Whilst it makes sense to develop surveillance systems centered on hospitals, in the longer-term it would be helpful to include sentinel sites from community settings where the population attending may be systematically different from those who attend hospital (the authors allude to this in their manuscript).

**Introduction**

In the Introduction the authors cite cost as the major barrier to the establishment of an AMR surveillance system in high income countries. I think this is only part of the reason. Until recently AMR surveillance was not a high priority because the steady supply of new antibiotics meant that drug resistance did not really matter – you could simply use a different drug.
Desk-based analysis and conceptual model

It would be helpful if the authors provide a list of experts involved in developing the conceptual model. More information on a) which databases and resources were searched for articles and information and b) which references were used to derive the results. Examples were clarification is desirable include:

- The finding by the authors that in Africa “… capacity is being developed …” currently appears to be solely based on one extensive example from Ghana. Stating that capacity is developed based on 1/47 states possibly overstates the true development.
- No numbers were provided for South-East Asia, although numerical summaries are available for Africa. Numbers were provided for Africa, but not for South-East Asia. Assuming that both are based on the WHO report (in the absence of other reference except for a workshop report from Cambodia), it is unclear why no numbers can be provided for South-East Asia to facilitate comparison.
- It is unclear what data was used to identify the listed “emerging themes”. Some of the points seem to draw on the case studies, e.g. Training: "Well-trained staff are likely to move elsewhere for better salaries, …” which is featured in the case studies for Malawi and Ethiopia.
- Further, it is unclear how model options were identified and summarised. Are they theory based (no reference is given) or are they based on observation of models in the countries of interest? Are they exhaustive?

Analytical framework

It is currently unclear how the functions, sub-functions and activities needed for AMR surveillance were identified? It would be helpful to include some more detail on how this was developed.

Costs

No discussion is included on how representative and generalizable costs based on a highly functioning site in Kenya can be expected to be. This would be valuable in judging the extrapolation of costs to other countries (both those included in the study as well as others).

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

Not applicable

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.
We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
supplies necessary to carry out the work are not there.

In the section on country case studies, the target audience for the author’s considerations and recommendations is not clear. Is this meant for the general reader to consider, when making surveillance plans? Is this a message to the governments of each respective country? Researchers? It would be helpful to understand better to whom these recommendations are being made, in order to ensure they reach their target.

For the costing results, the first 2 sentences might belong better in the methods. Also, it would help the reader to understand why these assumptions (1 sentinel site per 5 million people, 5 sites per country) were made – is this standard? I think it would also be helpful to present some of the actual projected costs of starting and maintaining AMR surveillance at 1 or more sites based on the costing analysis undertaken. The current discussion is theoretical, but without showing the funds needed to begin/continue AMR surveillance, it is hard to know how much of a burden this might represent for governments or other organizations, and what it would take to get started.

**Conclusions:** The authors highlight themes for success in AMR surveillance and challenges that are common across sites, and also those that differ between sites. Here, they also acknowledge the human resource deficit that has a particularly negative impact on developing laboratory capacity for AMR surveillance, a critically important theme. I would like to see the authors give perspective on what the cost, staffing, and infrastructure thresholds would be in order for countries to adopt an AMR surveillance program. The authors discuss high-level expertise in-country and engagement with ministries of health as important steps, but they don’t discuss the costs or practical trade-offs of what this would look like in any of the countries studied, or others. It would be nice to have a more definitive recommendation or understanding of what is possible in specific places, rather than only a general overview stating the importance of engaging multiple stakeholders.

**Is the work clearly and accurately presented and does it cite the current literature?**
Yes

**Is the study design appropriate and is the work technically sound?**
Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**
Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**
Not applicable

**Are all the source data underlying the results available to ensure full reproducibility?**
Yes

**Are the conclusions drawn adequately supported by the results?**
Yes

**Competing Interests:** No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
Elizeus Rutebemberwa
Makerere University School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda

Thank you for giving me the opportunity to review this interesting article on; “Supporting surveillance capacity for antimicrobial resistance: Laboratory capacity strengthening for drug resistant infections in low and middle income countries”. It is interesting to read. However certain areas need to be strengthened.

1. The title is a mouthful. I may not have a better format but a mechanism to remove repeated words like ‘capacity’ may generate a more focused title.

2. One silent feature of the write-up is surveillance in animals and the environment. In this era of sustainable development goals that looks at a more comprehensive perspective of human health and actively interacting and interfacing with the environment, surveillance for antimicrobial resistance would fall short if it does not put into consideration the use of antibiotics in the environment and how these affect resistance in humans. As a scientific article, it may be helpful to refer to sources of antimicrobial resistance outside the human health care system.

3. It is good the authors talk about the relevance of governance and legislation in the conclusion. The legal framework and enforcement are key factors in antibiotic use. Some more details on this in the body would be helpful to the reader.

4. The methods section is not written in sufficient detail for the reader to replicate the study. Suffice it to say that one may need to read the report to get the details but if the manuscript is to stand on its own, more details need to be inserted.

5. The presentation may need some improvement. Tables are given and can be easily understood. However, when reports are referred to, there is no mention of the highlights from the report in the manuscript. The reader has to click onto the links and read the reports before understanding the text. If some highlights on what the reader expects to pick from the reports are put in the text, this could prime the readers to go to these reports for more detailed information.

6. The discussion seems to be merged with the results which is fine. However, an interrogation of the findings vis-à-vis current literature would be helpful. Six of the 14 references are reports. More citations from laboratory surveillance studies would help in strengthening the discussion especially that the scope is low and middle income countries which are many more than the three or four countries where data was collected.

7. This may depend on the house rules but for the reader to go systematically through the writing, one would benefit from the results and discussion being presented with respect to the objectives namely; i) To map and compare existing models for laboratory system strengthening (for AMR
7. To map and compare existing AMR surveillance systems in at least three countries, identifying different approaches for monitoring emergence and spread of resistance in different countries or regional settings. The results are presented according to the data collection methods and a reader would still want to put all the results together synthesize them according to the objectives stated so that they key findings coming out can be discussed with reference to other current literature.

8. The authors present an interesting conceptual framework. The use of this framework in the data collection and results comes out although not in a systematic way. However, this could be due to the way results were presented which is according to data collection methods and not the conceptual framework. If the authors abide by the house rules, that would be fine although presenting results taking into consideration the conceptual framework helps readers to follow the story better.

Is the work clearly and accurately presented and does it cite the current literature? 
Partly

Is the study design appropriate and is the work technically sound? 
Partly

Are sufficient details of methods and analysis provided to allow replication by others? 
No

If applicable, is the statistical analysis and its interpretation appropriate? 
I cannot comment. A qualified statistician is required.

Are all the source data underlying the results available to ensure full reproducibility? 
Yes

Are the conclusions drawn adequately supported by the results? 
Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Health systems

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.